4/8/2010

Pfizer reached a deal with biotech firms MicuRx Pharmaceuticals and Cumencor Pharmaceuticals to develop antibiotics for drug-resistant tuberculosis in China. The collaboration is in line with Pfizer's plan to design more medicines that target diseases common in Asia.

Related Summaries